Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1Since this trial has completed recruitment and was primarily measuring treatment-related side effects and lab abnormalities from sitravatinib, has the safety data been published yet, and what does it show about the kinds of adverse events patients experienced?
2. 2This was a Phase 2/3 rollover study for people already receiving benefit from a parent trial — does my current treatment situation or prior therapy history make sitravatinib's safety profile more or less relevant to me?
3. 3Because the primary outcomes were focused on adverse events rather than survival or tumor response, what do we actually know so far about whether sitravatinib provides a meaningful clinical benefit for my specific cancer type?
4. 4Given that the trial is now completed, would you be able to access any results or data from this study that could inform whether sitravatinib might be worth discussing as part of my treatment plan?
5. 5Are there currently approved standard-of-care treatments for my cancer that have a more established benefit-and-risk profile compared to what was being studied in this sitravatinib trial?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.